Keytruda combo cleared as first-line kidney cancer treatment in EU

Merck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in the EU, putting further pressure on rival Bristol-Myers Squibb.